640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients wi...
640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundCOM701, a novel, first in-class immune checkpoint inhibitor, anti-PVRIG, that leads to activation of T-cells. PVRL2, the ligand of PVRIG, is highly expressed in breast cancer. We have reported preliminary antitumor activity with objective responses [partial responses and a complete response] in patients with solid tumors (MSS-CRC, platinu...
Alternative Titles
Full title
640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_363ff12d124c4f2cbb2ae653c202e261
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_363ff12d124c4f2cbb2ae653c202e261
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0640
